Basel Tops europe’s Rankings as the Premier Hub for Drug Device Innovation
New research unveiled ahead of Pharmapack Europe 2025 has crowned the Basel region as the most attractive destination in Europe for launching a new drug device company. The study, which surveyed over 280 global pharmaceutical executives, evaluated key factors such as plant costs, access to skilled personnel, and operational expenses. Basel emerged as the clear leader,securing one-third of the votes,ahead of Lombardy (18%),Catalunya (17%),the UK’s Golden Triangle (15%),and Germany’s Baden-Württemberg (14%).The findings highlight Basel’s unique strengths, including its unrivalled access to qualified personnel and world-class research infrastructure. Despite higher labor costs, the region’s ability to foster innovation and collaboration has solidified its position as a global leader in pharmaceutical and med-tech innovation.
Why Basel Stands Out
Table of Contents
Basel’s success is rooted in its rich history of pharmaceutical innovation and its ability to integrate precision engineering from industries like watchmaking into biomedical applications. Stèfan Halbherr, CEO of innomedica, a Swiss-based biotech company, emphasized this unique advantage: “Switzerland offers an exceptional foundation in manufacturing precision machinery. For example, to develop our unique approach to nanoparticle device filling, we collaborated with a manufacturer specializing in the production of small, highly precise machinery traditionally used in watchmaking.”
This cross-industry collaboration is driving the next generation of med-tech innovation, notably in precision medicine and personalized medicine applications. Smaller companies are leveraging these techniques to create groundbreaking devices and packaging solutions, further cementing Basel’s reputation as a hub for cutting-edge development.
Pharmapack europe: A Catalyst for Innovation
scheduled for 22-23 January 2025 at the Paris Expo, Pharmapack Europe is Europe’s premier pharmaceutical event, bringing together start-ups, investors, and industry leaders. The event’s Start-Up Hub will host over 20 emerging companies,with increasing participation from German and swiss executives seeking new development and licensing opportunities.
Sherma Ellis-Daal, brand director at Pharmapack Europe, highlighted the event’s role in fostering innovation: “As one of the few places where early-stage innovators can meet with investors and scale-up partners, we play a vital role in propagating drug delivery innovation. This research identifies the optimal locations for discovering and developing the next generation technologies for a novel device or new packaging—from concept to commercialization.”
Key Insights from the Pharmapack Report 2024
The full results of the Pharmapack Report 2024 and Index will be released during the event on CPHI-online. Below is a summary of the key findings:
| Rank | Region | Percentage of Votes |
|———-|————————|————————–|
| 1 | Basel,Switzerland | 33% |
| 2 | Lombardy,Italy | 18% |
| 3 | Catalunya,Spain | 17% |
| 4 | UK’s Golden Triangle | 15% |
| 5 | Baden-Württemberg,Germany | 14% |
A Bright Future for Biomanufacturing
In addition to its leadership in drug device innovation,Switzerland and Germany were also identified as the top regions for building new biomanufacturing facilities. Basel’s combination of skilled personnel, research excellence, and infrastructure continues to attract global attention, positioning it as a cornerstone of the pharmaceutical industry.
join the Innovation Movement
Pharmapack Europe 2025 is expected to draw over 6,000 attendees and 370 companies,making it the ideal platform for networking,collaboration,and discovery. Whether you’re an early-stage innovator or an established industry leader, this event offers unparalleled opportunities to shape the future of drug delivery and lasting packaging.Don’t miss your chance to be part of this transformative event. Register today and explore the full Pharmapack Report 2024 on CPHI-online.Together, we can drive the next wave of med-tech innovation and redefine the future of healthcare.
Basel Emerges as Europe’s Leading Hub for Drug Device Innovation: an Expert Interview
In a recent study unveiled ahead of pharmapack Europe 2025, the Basel region has been crowned as the most attractive destination in Europe for launching a new drug device company.This recognition stems from its unparalleled access to skilled personnel, world-class research infrastructure, and a collaborative environment that drives med-tech innovation.To delve deeper into these findings, we spoke with dr. Matthias Keller, a renowned expert in pharmaceutical innovation and a key figure in Basel’s thriving biotech ecosystem.
Why Basel is the premier Destination for Drug Device innovation
Senior Editor: Dr. Keller, what factors do you believe have contributed to basel’s rise as Europe’s top hub for drug device innovation?
Dr. Matthias Keller: Basel’s success is deeply rooted in its rich history of pharmaceutical innovation.The region is home to global pharmaceutical giants and a vibrant startup ecosystem, which fosters collaboration and knowledge-sharing. Additionally, Basel’s ability to integrate precision engineering from industries like watchmaking into biomedical applications has been a game-changer. This cross-industry expertise allows companies to develop cutting-edge devices with unparalleled precision.
Cross-Industry Collaboration: The Secret Behind Basel’s Success
Senior Editor: Can you elaborate on how cross-industry collaboration is driving innovation in Basel?
Dr. Matthias Keller: Absolutely.Take, for example, the work being done by companies like innomedica. They’ve collaborated with precision machinery manufacturers traditionally focused on watchmaking to develop innovative nanoparticle device filling techniques. This synergy between industries is accelerating advancements in precision medicine and personalized medicine applications, enabling smaller companies to create groundbreaking devices and packaging solutions.
pharmapack Europe 2025: A Catalyst for Innovation
Senior Editor: How do events like Pharmapack Europe 2025 contribute to Basel’s innovation ecosystem?
Dr. Matthias Keller: Pharmapack is a crucial platform for fostering collaboration and showcasing emerging technologies. The event’s Start-Up Hub provides early-stage innovators with the opportunity to connect with investors and industry leaders, facilitating the progress and commercialization of novel drug delivery solutions. With increasing participation from German and Swiss executives, Pharmapack is a vital catalyst for innovation in the region.
Key Insights from the Pharmapack Report 2024
Senior Editor: The Pharmapack Report 2024 highlights Basel as the clear leader in drug device innovation. What does this mean for the region’s future?
Dr.Matthias Keller: This recognition solidifies Basel’s position as a global leader in the pharmaceutical and med-tech sectors. The region’s combination of skilled personnel, research excellence, and infrastructure continues to attract global attention, making it an ideal location for building new biomanufacturing facilities. This is a testament to Basel’s ability to drive the next wave of med-tech innovation.
Joining the Innovation movement
Senior Editor: For those looking to be part of this transformative movement, what opportunities does Pharmapack Europe 2025 offer?
Dr. matthias Keller: Pharmapack Europe 2025 is expected to draw over 6,000 attendees and 370 companies,making it the ideal platform for networking,collaboration,and revelation. Whether you’re an early-stage innovator or an established industry leader, this event offers unparalleled opportunities to shape the future of drug delivery and lasting packaging. I encourage everyone to explore the full Pharmapack Report 2024 on CPHI-online and join us in redefining the future of healthcare.
Thank you, Dr. Keller, for yoru insights. it’s clear that Basel’s unique strengths and collaborative ecosystem are driving innovation in the pharmaceutical and med-tech sectors, solidifying its position as Europe’s premier hub for drug device innovation.
